PureTech Health Presents Data Supporting Treatment Approach for Interstitial Cystitis/Bladder Pain Syndrome Based on Novel Al...
July 13 2017 - 2:00AM
Business Wire
Clinical Advisory Board formed as product
candidate ALV-107 advanced for the treatment of Interstitial
Cystitis/Bladder Pain Syndrome
PureTech Health plc (“PureTech Health” or the “Company”, LSE:
PRTC), an advanced, clinical-stage biopharmaceutical company, today
presented data for product candidate ALV-107 showing durable pain
control throughout a 24-hour study period, lasting at least 12
times longer than lidocaine at a comparable dose (ALV-107 16 mg/kg,
conventional lidocaine 16 mg/kg), in a validated preclinical model
for the treatment of interstitial cystitis/bladder pain syndrome
(IC/BPS). ALV-107 utilizes the proprietary Alivio
inflammation-targeting technology. The data were presented at the
2017 Drug Discovery and Therapy World Congress in Boston,
Massachusetts.
“One of the greatest needs in urology is for a targeted therapy
that can relieve the pain and inflammation of interstitial
cystitis/bladder pain syndrome for extended periods of time,” said
J. Curtis Nickel, Professor and CIHR Tier 1 Canada Research Chair
in Urologic Pain and Inflammation at Queen’s University and
Clinical Advisory Board member. “These promising, preclinical
results suggest that ALV-107 may offer long-lasting relief for the
many who suffer from this chronic and debilitating disease. I look
forward to the acceleration of ALV-107 into the clinic and to
exploring the full potential application of this targeted treatment
approach.”
Pain levels, as measured by the mean nociceptive threshold, were
statistically indistinguishable between the pain-free baseline and
the ALV-107-treated group (n=8; at 2 hr, p=0.80; 4 hr, p=0.99; 24
hr, p=0.99). In contrast, the conventional lidocaine-treated group
was only statistically indistinguishable from the pain-free
baseline at 2 hours post-treatment (p=0.87). Furthermore, ALV-107
relieved pain at all studied time points post-therapy (vs.
vehicle-only control: at 2 hr, p=0.002; 4 hr, p=0.002; 24 hr,
p=0.0003). In contrast, the conventional lidocaine-treated group
showed statistically significant pain relief only 2 hours
post-treatment (p=0.03).
The Alivio technology is designed to adhere selectively to
inflamed tissue and remain adhered to deliver the incorporated
medication based on the levels of inflammation, potentially
enabling improved properties for the drug while minimizing its
exposure to healthy tissue and systemic side effects. Inflammation
is a key feature of IC/BPS, which is a chronic condition affecting
as many as 12 million people in the US and is characterized by
recurring pelvic pain and frequent urination. Current treatments
fail to control pain in many patients, particularly patients with
Hunner’s lesions, which is estimated to affect between 5-10% of
IC/BPS patients in the US.
To support this program in IC/BPS, PureTech Health has formed a
Clinical Advisory Board consisting of key experts who have played a
seminal role in the research and development of various medical
therapies for several chronic pelvic pain conditions, including
IC/BPS:
- J. Curtis Nickel, MD, FRCSC – Professor
and CIHR Tier 1 Canada Research Chair in Urologic Pain and
Inflammation at Queen’s University (Kingston, ON)
- Kenneth Peters, MD – Professor and
Chairman of Urology at the Oakland University William Beaumont
School of Medicine (Auburn Hills, MI)
- Robert M. Moldwin, MD, FACS – Director,
Pelvic Pain Treatment Center at the Arthur Smith Institute for
Urology and Associate Professor of Urology at the Hofstra Northwell
School of Medicine
The Alivio technology was exclusively licensed from the lab of
Jeff Karp, Ph.D., Associate Professor at Brigham and Women's
Hospital (BWH), Harvard Medical School. In March of 2017, the Bill
& Melinda Gates Foundation awarded a $1.2 million grant to
Professor Jeff Karp’s Lab at BWH to support additional research on
the technology.
About the Alivio TechnologyThe Alivio technology is a
proprietary hydrogel technology being developed for the targeted
treatment of chronic and acute inflammatory disorders. It is
designed to adhere to inflamed tissue and remain adhered to deliver
incorporated medication based on the levels of inflammation,
potentially enabling improved properties of the medication while
minimizing exposure to healthy tissue and systemic side effects.
Alivio technology could potentially be used with a variety of
medications (e.g., small molecules, peptides, proteins and nucleic
acids) addressing dozens of conditions where inflammation is a
central part of the underlying disease pathology, but where
targeted and effective treatment options are lacking.
The Alivio technology is being developed in collaboration with
several of the world’s leading experts in biomaterials and
immunology. Expert advisors include: Jeff Karp, Ph.D., Principal
Investigator Karp Lab; Robert Langer, Sc.D., Co-Founder and
Non-Executive Director at PureTech Health and David H. Koch
Institute Professor at MIT; Michael B. Brenner, M.D., Chief of the
Division of Rheumatology, Immunology and Allergy at BWH; Ulrich H.
von Andrian, M.D., Ph.D., Mallinckrodt Professor of Immunopathology
at Harvard Medical School; and Ralph Weissleder, M.D., Ph.D.,
Director of the Center for Systems Biology at Massachusetts General
Hospital.
About PureTech HealthPureTech Health (PureTech Health
plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical
company developing novel medicines targeting serious diseases that
result from dysfunctions in the immune, nervous, and
gastro-intestinal systems by intervening early and addressing the
underlying pathophysiology of disease. The Company is advancing a
rich pipeline that includes two pivotal or registration studies
expected to read out in 2017, multiple human proof-of-concept
studies and a number of early clinical and pre-clinical programs.
PureTech Health’s growing research and development pipeline has
been developed in collaboration with some of the world’s leading
scientific experts, who along with PureTech's experienced team and
a stellar Board identify, analyze and advance very selectively the
opportunities the Company believes hold the most promise for
patients. This experienced and engaged team places PureTech Health
at the forefront of ground-breaking science and technological
innovation and leads the Company between and beyond existing
disciplines. For more information, visit www.puretechhealth.com or
connect with us on Twitter @puretechh.
Forward Looking StatementThis press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company's future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks and uncertainties that could cause actual results,
performance and achievements to differ materially from current
expectations, including, but not limited to, those risks and
uncertainties described in the risk factors included in the
regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170712006354/en/
PureTech HealthAllison Mead, +1
617-651-3156amead@puretechhealth.comorFTI ConsultingBen
Atwell or Rob Winder, +44 (0) 20 3727 1000
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024